Relpax (Eletriptan Hydrobromide) Patent Expiration, LOE Window & CMS Spending

Relpax (Eletriptan Hydrobromide) by Viatris: Off-Patent Genericized (AB Competition), 7 AB generics, $7.1M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorViatris
FDA Application & PathwayN021016 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$7.1M
2024 Medicare Part D Spend$2.8M
2024 Medicaid Spend$4.3M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 17.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.